Dry Age-Related Macular Degeneration Market-Forecast till 2027
Dry Age-Related Macular Degeneration Market Forecast
According to this report, the global dry age-related macular degeneration market is projected to witness a significant CAGR of 8.62% during the review period to surpass USD 6,113.33 million by the end of 2027. Dry macular degeneration is a typical eye issue among individuals aged more than 50. The macula is the piece of the retina answerable for clear vision in your immediate view.
The development of the worldwide dry Age-related Macular Degeneration market is ascribed to the developing geriatric populace and expanding pervasiveness old enough related macular degeneration, and the presentation of novel treatment techniques for dry AMD combined with the expanding number of clinical preliminaries zeroed in on dry AMD.
Different variables like expanding medical services use are probably going to assist the market with developing. In any case, a large number of bombed clinical preliminaries for dry AMD medications may hamper the market development somewhat. The global market expansion is propelled by the growing geriatric population and rising incidences of dry age-related macular degeneration.
The global dry age-related macular degeneration AMD market has been divided based on stages, age group, route of administration, diagnosis & treatment, and end-user.
Based on Stages the global market has been classified into Early stage of AMD, Intermediate Stage of AMD, and Late Stage of AMD.
By age group segment, the global market is categorized into above 75 years, above 60 years, and above 40 years.
In terms of diagnosis & treatment, the dry age-related macular degeneration AMD market is bifurcated into treatment and diagnosis.
The treatment is further classified into nutrition therapy and telescopic lens implant. The nutrition therapy segment is sub-segmented into antioxidants and others. Based on the route of administration, the market is divided into oral and injectables.
In terms of end-user, the market is categorized into hospitals &clinics, diagnostic centers, academic &research institutes, and others.
Based on region, the global dry AMD market has been classified into North America, Europe, Asia-Pacific, and the Rest of the World.
North America is likely to drive the largest market for global dry AMD owing to the government initiatives and funding in the region. Europe holds the second biggest portion of the overall industry because of the expanding more seasoned populace and rising patient populace.
Furthermore, further developing government drives, expanding medical care casings, and rising interest for mechanically inventive therapy are driving the development of the dry age-related macular degeneration market in Europe. The Asia-Pacific exhibits the rapidly developing business sector for age-related macular degeneration as it is creating at an exceptionally fast speed and has shown the rise of numerous players.
Major players of the global dry age-related macular degeneration market are Santen Pharmaceuticals Inc. (Japan), Allergan plc (Ireland), Bausch Health (Canada), Alimera Science Inc. (US), Phio Pharmaceuticals Corp (US), Ocumension Therapeutics Co. Ltd (China), Belite Bio Inc. (US), Kubota Vision Inc. (US), Iveric Bio (US), Eyestem Research Pvt Ltd (India), Yuyang DNU Co., Ltd (South Korea), and Stealth Biotherapeutics Inc. (US)
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.
Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.